市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Pharvaris N.V. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | -3.0 |
| 价格波动 | -3.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.13 |
|
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 6.25% |
| 机构持股比例 | 89.49% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Foresite Capital Management Iv, Llc | 30 Jun 2026 | 4,778,581 |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| LU PENG | - | 37.84 | -15,000 | -567,600 |
| 累积净数量 | -15,000 | |||
| 累积净值 ($) | -567,600 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 37.84 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| LU PENG | 职员 | 08 Sep 2026 | 自动卖出 (-) | 15,000 | 37.84 | 567,600 |
| LU PENG | 职员 | 08 Sep 2026 | 执行期权 | 15,000 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合